UY35418A - Vacuna que proporciona protección frente a diferentes Picornavirus humanos. - Google Patents
Vacuna que proporciona protección frente a diferentes Picornavirus humanos.Info
- Publication number
- UY35418A UY35418A UY0001035418A UY35418A UY35418A UY 35418 A UY35418 A UY 35418A UY 0001035418 A UY0001035418 A UY 0001035418A UY 35418 A UY35418 A UY 35418A UY 35418 A UY35418 A UY 35418A
- Authority
- UY
- Uruguay
- Prior art keywords
- vaccine
- protection against
- provides protection
- different human
- against different
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
- C07K14/095—Rhinovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
La divulgación proporciona composiciones inmunogénicas que comprenden péptidos de picornavirus humanos derivados de proteínas estructurales del virus, constructos que comprenden los péptidos, los péptidos mismos y su uso en la prevención de infecció n y enfermedad por picornavirus. Se dan a conocer péptidos particulares de VP4 y VP1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361786765P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35418A true UY35418A (es) | 2014-10-31 |
Family
ID=50382421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035418A UY35418A (es) | 2013-03-15 | 2014-03-13 | Vacuna que proporciona protección frente a diferentes Picornavirus humanos. |
Country Status (8)
Country | Link |
---|---|
US (2) | US10058603B2 (es) |
EP (2) | EP3608332B1 (es) |
AR (1) | AR095425A1 (es) |
BE (1) | BE1022174B1 (es) |
ES (1) | ES2924914T3 (es) |
TW (1) | TW201502136A (es) |
UY (1) | UY35418A (es) |
WO (1) | WO2014140166A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016134288A1 (en) * | 2015-02-19 | 2016-08-25 | University Of Virginia Patent Foundation | Compositions and methods for preventing and treating rhinovirus infections |
RU2617043C1 (ru) * | 2016-03-24 | 2017-04-19 | Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский и технологический институт биологической промышленности" (ФГБНУ ВНИТИБП) | Вакцина против ящура и способ её получения и применения |
WO2018002902A1 (en) | 2016-07-01 | 2018-01-04 | Glaxosmithkline Intellectual Property (No.2) Limited | Antibody-drug conjugates and therapeutic methods using the same |
GB201616904D0 (en) * | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
WO2023114951A1 (en) | 2021-12-17 | 2023-06-22 | Viiv Healthcare Company | Combination therapies for hiv infections and uses thereof |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8821077D0 (en) * | 1988-09-08 | 1988-10-05 | Wellcome Found | Peptides |
SE470074B (sv) | 1990-08-16 | 1993-11-01 | Replico Medical Ab | Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider |
WO1993010152A1 (en) | 1991-11-16 | 1993-05-27 | Smithkline Beecham Biologicals S.A. | HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG |
DE69405551T3 (de) | 1993-03-23 | 2005-10-20 | Smithkline Beecham Biologicals S.A. | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
SI0729473T1 (en) | 1993-11-17 | 2001-02-28 | Om Pharma | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
AU7924598A (en) | 1998-06-08 | 1999-12-30 | Sca Emballage France | Fast flattening packaging |
DK1091928T3 (da) | 1998-06-30 | 2007-07-23 | Om Pharma | Nye acylerede pseudodipeptider, fremgangsmåde til disses fremstilling og sammensætninger, som indeholder dem |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
WO2001046127A1 (fr) | 1999-12-22 | 2001-06-28 | Om Pharma | Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise |
AU2002245636B2 (en) | 2001-03-09 | 2004-10-14 | Id Biomedical Corporation Of Quebec | A novel proteosome-liposaccharide vaccine adjuvant |
CN1250548C (zh) | 2001-04-17 | 2006-04-12 | 大日本住友制药株式会社 | 新的腺嘌呤衍生物 |
DE60230340D1 (de) | 2001-11-16 | 2009-01-22 | 3M Innovative Properties Co | N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung |
EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8 |
GB0420634D0 (en) | 2004-09-16 | 2004-10-20 | Glaxosmithkline Biolog Sa | Vaccines |
WO2006078648A2 (en) * | 2005-01-19 | 2006-07-27 | Donald Danforth Plant Science Center | Rhinovirus vaccines |
GB0505996D0 (en) | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Fermentation process |
MX2009003301A (es) | 2006-09-29 | 2009-07-15 | Sanofi Pasteur Biologics Co | Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas. |
WO2009127081A1 (en) * | 2008-04-17 | 2009-10-22 | Biomerieux | A newly identified human rhinovirus of hrv-c and methods and kits for detecting hrv-cs |
GB0815872D0 (en) * | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
EP2316481A1 (en) | 2009-10-30 | 2011-05-04 | Biomay Ag | Pharmaceutical composition for the treatment and prevention of a rhinovirus infection |
MX356426B (es) * | 2011-04-04 | 2018-05-29 | Univ Iowa Res Found | Metodos para mejorar inmunogenicidad de vacuna. |
KR101895768B1 (ko) * | 2011-06-01 | 2018-09-07 | 시아먼 유니버시티 | 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질 |
WO2013019603A2 (en) * | 2011-07-29 | 2013-02-07 | Inovio Pharmaceuticals, Inc. | Linear expression cassettes and uses thereof |
-
2014
- 2014-03-13 TW TW103109181A patent/TW201502136A/zh unknown
- 2014-03-13 US US14/774,729 patent/US10058603B2/en active Active
- 2014-03-13 EP EP19198428.5A patent/EP3608332B1/en active Active
- 2014-03-13 EP EP14712621.3A patent/EP2968521A2/en not_active Ceased
- 2014-03-13 AR ARP140100969A patent/AR095425A1/es unknown
- 2014-03-13 UY UY0001035418A patent/UY35418A/es not_active Application Discontinuation
- 2014-03-13 ES ES19198428T patent/ES2924914T3/es active Active
- 2014-03-13 WO PCT/EP2014/054947 patent/WO2014140166A2/en active Application Filing
- 2014-03-13 BE BE2014/0161A patent/BE1022174B1/fr not_active IP Right Cessation
-
2018
- 2018-08-17 US US16/104,226 patent/US10493145B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW201502136A (zh) | 2015-01-16 |
BE1022174B1 (fr) | 2016-02-24 |
US10058603B2 (en) | 2018-08-28 |
EP3608332B1 (en) | 2022-06-01 |
US20190076519A1 (en) | 2019-03-14 |
EP2968521A2 (en) | 2016-01-20 |
EP3608332A1 (en) | 2020-02-12 |
AR095425A1 (es) | 2015-10-14 |
US20160022803A1 (en) | 2016-01-28 |
WO2014140166A2 (en) | 2014-09-18 |
US10493145B2 (en) | 2019-12-03 |
WO2014140166A3 (en) | 2014-11-20 |
ES2924914T3 (es) | 2022-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2021000022A (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
BR112018012873A2 (pt) | vacina de vírus zika | |
BR112018011122A2 (pt) | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos | |
PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
UY35418A (es) | Vacuna que proporciona protección frente a diferentes Picornavirus humanos. | |
AR101814A1 (es) | Partícula de tipo virus flavivirus | |
EA201290956A1 (ru) | Вакцина против вич | |
CU20180035A7 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
BR112017004197A2 (pt) | composições de vacina contra doenças do vírus da dengue | |
CU20180025A7 (es) | Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue | |
NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
DK3146042T3 (da) | Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop | |
CO7461135A2 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
CR20160495A (es) | Composiciones libres de células para la restauración de células y métodos para la preparación y utilización de las mismas | |
MX2016002903A (es) | Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah. | |
MX363149B (es) | Vacunas de nucleoproteina de la influenza. | |
EA201790771A1 (ru) | Фармацевтические композиции длительного действия для лечения гепатита c | |
EA201790776A1 (ru) | Комбинированные композиции длительного действия и способы лечения гепатита с | |
AR094846A1 (es) | Proteínas h5 del virus de la gripe h5n1 para uso como un medicamento | |
EA201992167A1 (ru) | Вакцина | |
CL2018001201A1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas. | |
AR111011A1 (es) | Poxvirus quiméricos sintéticos | |
EA202191862A2 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
CL2010001151A1 (es) | Formulacion que comprende los segmentos proteicos nhe, che, nnp, m1 y fp2 del virus isa; vacuna recombinante que la comprende; procedimiento de preparacion; y uso para prevenir o tratar infeccion por virus isa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20211112 |